YOLFTbeta
30

Kingchem (Liaoning) Life Science Co., Ltd.

301509 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

25.81CNY-0.51 (-1.94%)

Price History

Full chart

Market Stats

Previous Close26.32
Open26.52
Day Range25.65 – 26.91
52-Week Range23.80 – 47.14
Volume2.51M
Market Cap3.15B
P/E (TTM)70.65
Forward P/E0.00
EPS0.37
Dividend Yield3.44%
Beta0.44
50-Day Avg28.48
200-Day Avg32.85

About

Kingchem (Liaoning) Life Science Co., Ltd. engages in the provision of small molecule CDMO services in China and internationally. The company offers fluorine-containing products, such as benzene intermediates of trifluoromethoxy or trifluoromethyl groups, and fluoroaromatic intermediates. It also provides non-fluorinated products, including nitrogen-containing heterocyclic compounds, aliphatic organic derivatives of ammonia, carboxylic acids and their derivatives, alkenes, non-fluorinated halobenzenes, phenols, ketones, and isocyanates. The company serves pharmaceuticals, pesticides, and specialty chemicals industries. Kingchem (Liaoning) Life Science Co., Ltd. was founded in 2009 and is headquartered in Fuxin, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Fumin Wang
  • Employees690
  • HeadquartersFluorine Chemical Industrial Park, Fuxin, China, 123129, China
  • Websitehttps://www.kingchemchina.com

Leadership

  • Mr. Fumin WangChairman of the Board & President · b. 1963
  • Ms. Lianping WuVice Chairman & COO · b. 1963
  • Mr. Wang QiFinancial Director & Secretary · b. 1970
  • Mr. Tiecheng JiaVP & Director · b. 1977
  • Mr. Yongcan WangVice President · b. 1977
  • Shi BoChief Scientist (CSO)

Financials

Income Statement

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Total Revenue716.67M766.82M497.01M639.37M
Growth (%)-+7.00%-35.19%+28.64%
Cost of Revenue400.57M404.85M321.87M367.70M
Gross Profit316.10M361.98M175.14M271.67M
Gross Margin44.11%47.20%35.24%42.49%
Operating Expense134.12M152.34M145.48M158.16M
Operating Income181.98M209.63M29.66M113.51M
Operating Margin25.39%27.34%5.97%17.75%
EBITDA253.12M273.71M107.01M183.58M
EBITDA Margin35.32%35.69%21.53%28.71%
Net Income161.45M173.57M38.61M104.81M
Net Income Margin22.53%22.64%7.77%16.39%
R&D25.99M30.04M35.53M35.91M
R&D as % of Total Revenue3.63%3.92%7.15%5.62%
Interest Expense5.42M2.20M321.81K193.02K
Interest Expense % of Total Revenue0.76%0.29%0.06%0.03%

Balance Sheet

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Total Assets1.21B2.31B2.26B2.32B
Total Liabilities331.21M139.63M114.57M112.70M
Total Equity878.79M2.17B2.15B2.21B
Cash231.01M486.90M191.18M370.74M

Cash Flow

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow241.55M155.16M154.90M170.20M
Capital Expenditure126.69M72.90M54.10M41.84M
Free Cash Flow114.86M82.26M100.80M128.36M
Dividends Paid4.11M2.20M69.15M48.37M
FCF to OCF47.55%53.02%65.08%75.42%
Dividend Paid to FCF3.58%2.68%68.60%37.68%

Earnings

Report DateSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
EPS Estimate-------------
EPS Actual0.280.230.140.130.06-0.010.390.200.260.010.140.110.11
Surprise-------------
Timing-------------

Key Statistics & Ratios

Market Cap3.15B
Enterprise Value2.23B
Trailing P/E70.65
Forward P/E0.00
Price / Sales5.11
Price / Book1.47
EPS0.37
Book Value17.74
Revenue (TTM)615.76M
Gross Profit (TTM)196.79M
EBITDA81.47M
Profit Margin7.33%
Operating Margin5.66%
Return on Equity2.08%
Return on Assets0.69%
Shares Outstanding120.45M
Shares Float56.74M
Beta0.44
Dividend Yield3.44%
Dividend Rate0.90
Payout Ratio2.40%